This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL)

Tipranks - Tue May 12, 8:44PM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ceribell, Inc. (CBLL) and AbCellera Biologics (ABCL) with bullish sentiments.

Claim 55% Off TipRanks

Ceribell, Inc. (CBLL)

TD Cowen analyst Josh Jennings maintained a Buy rating on Ceribell, Inc. today and set a price target of $29.00. The company’s shares closed last Monday at $20.06, close to its 52-week low of $18.69.

According to TipRanks.com, Jennings is a 1-star analyst with an average return of -1.5% and a 40.7% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ceribell, Inc. with a $29.00 average price target.

See Insiders’ Hot Stocks on TipRanks >>

AbCellera Biologics (ABCL)

TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics yesterday. The company’s shares closed last Monday at $5.25.

According to TipRanks.com, Smith is a 4-star analyst with an average return of 5.3% and a 43.3% success rate. Smith covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Recursion Pharmaceuticals, and Ginkgo Bioworks Holdings. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for AbCellera Biologics with a $8.00 average price target, representing a 46.1% upside. In a report issued on May 5, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $7.00 price target.

Read More on CBLL:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.